180 related articles for article (PubMed ID: 16369751)
1. 5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
Int J Clin Oncol; 2005 Dec; 10(6):441-3. PubMed ID: 16369751
[TBL] [Abstract][Full Text] [Related]
2. Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
Franck C; Malfertheiner P; Venerito M
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28536214
[TBL] [Abstract][Full Text] [Related]
3. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
4. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
5. Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.
Kim WY; Nakata B; Hirakawa K
Cancer Sci; 2007 Oct; 98(10):1604-8. PubMed ID: 17683513
[TBL] [Abstract][Full Text] [Related]
6. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
Nishikawa Y; Funakoshi T; Horimatsu T; Miyamoto S; Matsubara T; Yanagita M; Nakagawa S; Yonezawa A; Matsubara K; Muto M
Cancer Chemother Pharmacol; 2017 Mar; 79(3):629-633. PubMed ID: 28204913
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Sueda T; Kudo T; Sakai D; Uemura M; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Ezoe S; Matsumoto K; Doki Y; Mori M; Satoh T
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1321-4. PubMed ID: 25374410
[TBL] [Abstract][Full Text] [Related]
9. 5-fluorouracil-induced coronary vasospasm.
Shoemaker LK; Arora U; Rocha Lima CM
Cancer Control; 2004; 11(1):46-9. PubMed ID: 14749623
[TBL] [Abstract][Full Text] [Related]
10. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
12. [A case of colon cancer with multiple liver metastases responding ot S-1 as third-line treatment following FOLFIRI and FOLFOX].
Miyahira T; Teruya N; Matsuura F; Murayama S; Aka H; Teruya J; Hanashiro N; Nishihara M; Okushima N; Toda Y; Kiyuna M
Gan To Kagaku Ryoho; 2010 Feb; 37(2):331-4. PubMed ID: 20210032
[TBL] [Abstract][Full Text] [Related]
13. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
14. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
[TBL] [Abstract][Full Text] [Related]
16. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
Köhne CH; Thuss-Patience P; Friedrich M; Daniel PT; Kretzschmar A; Benter T; Bauer B; Dietz R; Dörken B
Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
18. A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
Nakamura M; Nagano H; Wada H; Noda T; Ota H; Damdinsuren B; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M
J Gastroenterol; 2006 Nov; 41(11):1120-5. PubMed ID: 17160524
[TBL] [Abstract][Full Text] [Related]
19. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Muneoka K; Shirai Y; Yokoyama N; Wakai T; Hatakeyama K
Gan To Kagaku Ryoho; 2005 Feb; 32(2):231-3. PubMed ID: 15751639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
